CD52 and neoplasm: However, there was a significant reduction in tumor size and volume in mice which were treated with combination CD5-2 and anti-PD1 antibody compared to other treatment groups including treatment groups with single active agents CD5-2 or anti-PD1 antibody (Figures 2B–D).